Highlights Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
4.42 ^USD	-0.45%		+0.68%	+3.76%

Apr. 08	Transcript : Inozyme Pharma, Inc. - Special Call
Apr. 08	Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency	Apr. 08	CI
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency	Mar. 26	CI
Inozyme Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions	23-10-10	CI
Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency	23-09-26	CI
Inozyme Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Inozyme Pharma Updates INZ-701 Development Plan After Meetings With US, EU Regulators; Shares Drop	23-07-26	MT
Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency	23-07-26	CI
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701	23-06-27	CI
Inozyme Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Inozyme Pharma, Inc. Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701	23-02-16	CI
Inozyme Pharma, Inc. Provides Business Updates	22-12-08	CI
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Inozyme Pharma, Inc. Announces First Self-Administration of Inz-701 in Ongoing Enpp1 Deficiency Phase 1/2 Clinical Trial	22-11-03	CI
Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database	22-10-31	CI
Inozyme Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)	22-07-19	CI
Inozyme Pharma to Work With Rady Children's Institute for Genomic Medicine on Newborn Screening Technology	22-06-16	MT
Inozyme Pharma Announces Partnership with Rady Children's Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases	22-06-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Highlights

Filters